The $150m venture financing of Mammoth Biosciences was the medical devices industry’s top Cross Border venture financing deal as total deals worth $632.1m were announced globally in September 2021, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 35.9% over the previous month of $985.41m and a drop of 42.01% when compared with the last 12-month average, which stood at $1.09bn.

Comparing cross border venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $461.45m. At the country level, the US topped the list in terms of deal value at $459.5m.

In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of cross border venture financing deals activity in September 2021 was the US with 11 deals, followed by the China with three and France with one.

In 2021, as of September, medical devices cross border venture financing deals worth $10.73bn were announced globally, marking a decrease of 47.4% year on year.

medical devices industry cross border venture financing deals in September 2021: Top deals

The top five medical devices industry cross border venture financing deals accounted for 64.9% of the overall value during September 2021.

The combined value of the top five medical devices cross border venture financing deals stood at $410m, against the overall value of $632.1m recorded for the month.

The top five medical devices industry cross border venture financing deals of September 2021 tracked by GlobalData were:

1) Decheng Capital,Foresite Capital Management,Greenspring Associates,Mayfield Fund,NFX partners,Plum Alley Investments,Redmile Group,Senator Investment Group and Sixth Street Partners $150m venture financing deal with Mammoth Biosciences

2) The $102m venture financing of INBRACE by BlackRock,Endeavour Vision,Farallon Capital Management,Marshall Wace,MVM Partners,Novo Ventures (US),RTW Investments,Soleus Capital Management,venBio and Vivo Capital

3) Horizon Ventures $58m venture financing deal with Owlstone Medical

4) The $55m venture financing of Francis Medical by Arboretum Ventures,Coloplast,H2Oey Ventures,Solas Bioventures and Tonkawa

5) CSIRO Financial Services,Horizons Ventures and JAADE Australian Private Assets Fund $45m venture financing deal with Prospection